Ads
related to: enfortumab vedotin success rate calculator 1 7- About PADCEV®
Discover How PADCEV® Treatment
May Work For You.
- PADCEV® Efficacy Info
Learn About How PADCEV® Was
Studied and View Trial Results.
- Patient Resources
Download Available Resources and
View Advocacy Group Information.
- View PADCEV® Side Effects
Review the Side Effect List & Other
Important Safety Information.
- About PADCEV®
Search results
Results from the WOW.Com Content Network
Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4] [7] It is a nectin-4-directed antibody and microtubule inhibitor conjugate. [4] [7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]
Monomethyl auristatin E is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin.The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism.
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. [1] It is a combination of tisotumab, a monoclonal antibody against tissue factor , and monomethyl auristatin E (MMAE), a potent inhibitor of cell division .
148 251.25 g·mol −1 Depatuxizumab mafodotin ( INN ; development code ABT-414 ) is an antibody-drug conjugate designed for the treatment of cancer. [ 1 ] [ 2 ] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.
[7] [14] The overall response rate in these adults was 32.2%, with 2.3% having a complete response and almost 30% having a partial response. [7] The response lasted for a median of approximately five-and-a-half months. [7] The trial was conducted in Asia, Europe, and the United States. [14] Erdafitinib received an accelerated approval. [7]
A phase 1 clinical trial in 2004 demonstrated the safety and tolerability of mapatumumab in cancer patients with advanced solid tumors or non-Hodgkin’s lymphoma, and supported further evaluation in phase 2 clinical trials, both as a single agent and in combination with chemotherapy. [4]
Ads
related to: enfortumab vedotin success rate calculator 1 7